Ron Rocca's Email & Phone

Before joining Exagen, Mr. Glenn was the founder and Managing Partner of Windamere Venture Partners. Companies in the Windamere portfolio raised in excess of $1 billion for emerging medical technology businesses. Mr. Glenn is also the past Chairman and founder of Prometheus Laboratories, Santarus (Nasdaq:SNTS), Dexcom (Nasdaq:DXCM), SpineWave, and Conception Technologies. In addition, he was a founder at Zogenix, NovaCardia (sold to Merck), Proprius (sold to Cypress), Somaxon Pharmaceuticals (Nasdaq:SOMX), Cadence Pharmaceuticals (Nasdaq:CADX and Avera Pharmaceuticals. Prior to his involvement in venture capital, he was the President and CEO of Quidel Corporation (Nasdaq:QDEL). Prior to Quidel, Mr. Glenn held various management positions including Division General Manager with Allergan Pharmaceuticals (NYSE: AGN). He serves as a director and founder of Evoke Pharmaceuticals and Planet Biopharmaceuticals.